
Global Passive Immunizing Drugs Market Outlook and Growth Opportunities 2025
Description
Summary
According to APO Research, the global Passive Immunizing Drugs market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Passive Immunizing Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for Passive Immunizing Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Passive Immunizing Drugs market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for Passive Immunizing Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Passive Immunizing Drugs market include Xingmeng Biopharmaceuticals (Suzhou), Wuhan Institute of Biological Products, Sichuan Yuanda Shuyang Pharmaceutical, Shanxi Kangbao Biological Product, Sharon Bio-Medicine, Hualan Biological Engineering, North China Pharmaceutical, Sinopharm Group and Zydus Lifesciences, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Passive Immunizing Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Passive Immunizing Drugs, also provides the sales of main regions and countries. Of the upcoming market potential for Passive Immunizing Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Passive Immunizing Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Passive Immunizing Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Passive Immunizing Drugs sales, projected growth trends, production technology, application and end-user industry.
Passive Immunizing Drugs Segment by Company
Xingmeng Biopharmaceuticals (Suzhou)
Wuhan Institute of Biological Products
Sichuan Yuanda Shuyang Pharmaceutical
Shanxi Kangbao Biological Product
Sharon Bio-Medicine
Hualan Biological Engineering
North China Pharmaceutical
Sinopharm Group
Zydus Lifesciences
Serum Institute of India
Sanofi Pasteur
Kedrion Biopharma
Kamada
Haffkine Bio-Pharmaceutical
Grifols
Bharat Biotech
Passive Immunizing Drugs Segment by Type
Rabies Immunoglobulin
Rabies Virus Monoclonal Antibody
Anti-rabies Serum
Passive Immunizing Drugs Segment by Application
Category II Exposure
Category III Exposure
Passive Immunizing Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Passive Immunizing Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Passive Immunizing Drugs market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Passive Immunizing Drugs significant trends, drivers, influence factors in global and regions.
6. To analyze Passive Immunizing Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Passive Immunizing Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Passive Immunizing Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Passive Immunizing Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Passive Immunizing Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Passive Immunizing Drugs industry.
Chapter 3: Detailed analysis of Passive Immunizing Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Passive Immunizing Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Passive Immunizing Drugs in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
According to APO Research, the global Passive Immunizing Drugs market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Passive Immunizing Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for Passive Immunizing Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Passive Immunizing Drugs market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for Passive Immunizing Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Passive Immunizing Drugs market include Xingmeng Biopharmaceuticals (Suzhou), Wuhan Institute of Biological Products, Sichuan Yuanda Shuyang Pharmaceutical, Shanxi Kangbao Biological Product, Sharon Bio-Medicine, Hualan Biological Engineering, North China Pharmaceutical, Sinopharm Group and Zydus Lifesciences, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Passive Immunizing Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Passive Immunizing Drugs, also provides the sales of main regions and countries. Of the upcoming market potential for Passive Immunizing Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Passive Immunizing Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Passive Immunizing Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Passive Immunizing Drugs sales, projected growth trends, production technology, application and end-user industry.
Passive Immunizing Drugs Segment by Company
Xingmeng Biopharmaceuticals (Suzhou)
Wuhan Institute of Biological Products
Sichuan Yuanda Shuyang Pharmaceutical
Shanxi Kangbao Biological Product
Sharon Bio-Medicine
Hualan Biological Engineering
North China Pharmaceutical
Sinopharm Group
Zydus Lifesciences
Serum Institute of India
Sanofi Pasteur
Kedrion Biopharma
Kamada
Haffkine Bio-Pharmaceutical
Grifols
Bharat Biotech
Passive Immunizing Drugs Segment by Type
Rabies Immunoglobulin
Rabies Virus Monoclonal Antibody
Anti-rabies Serum
Passive Immunizing Drugs Segment by Application
Category II Exposure
Category III Exposure
Passive Immunizing Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Passive Immunizing Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Passive Immunizing Drugs market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Passive Immunizing Drugs significant trends, drivers, influence factors in global and regions.
6. To analyze Passive Immunizing Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Passive Immunizing Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Passive Immunizing Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Passive Immunizing Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Passive Immunizing Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Passive Immunizing Drugs industry.
Chapter 3: Detailed analysis of Passive Immunizing Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Passive Immunizing Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Passive Immunizing Drugs in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
209 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Passive Immunizing Drugs Sales Value (2020-2031)
- 1.2.2 Global Passive Immunizing Drugs Sales Volume (2020-2031)
- 1.2.3 Global Passive Immunizing Drugs Sales Average Price (2020-2031)
- 1.3 Assumptions and Limitations
- 1.4 Study Goals and Objectives
- 2 Passive Immunizing Drugs Market Dynamics
- 2.1 Passive Immunizing Drugs Industry Trends
- 2.2 Passive Immunizing Drugs Industry Drivers
- 2.3 Passive Immunizing Drugs Industry Opportunities and Challenges
- 2.4 Passive Immunizing Drugs Industry Restraints
- 3 Passive Immunizing Drugs Market by Company
- 3.1 Global Passive Immunizing Drugs Company Revenue Ranking in 2024
- 3.2 Global Passive Immunizing Drugs Revenue by Company (2020-2025)
- 3.3 Global Passive Immunizing Drugs Sales Volume by Company (2020-2025)
- 3.4 Global Passive Immunizing Drugs Average Price by Company (2020-2025)
- 3.5 Global Passive Immunizing Drugs Company Ranking (2023-2025)
- 3.6 Global Passive Immunizing Drugs Company Manufacturing Base and Headquarters
- 3.7 Global Passive Immunizing Drugs Company Product Type and Application
- 3.8 Global Passive Immunizing Drugs Company Establishment Date
- 3.9 Market Competitive Analysis
- 3.9.1 Global Passive Immunizing Drugs Market Concentration Ratio (CR5 and HHI)
- 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
- 3.9.3 2024 Passive Immunizing Drugs Tier 1, Tier 2, and Tier 3 Companies
- 3.10 Mergers and Acquisitions Expansion
- 4 Passive Immunizing Drugs Market by Type
- 4.1 Passive Immunizing Drugs Type Introduction
- 4.1.1 Rabies Immunoglobulin
- 4.1.2 Rabies Virus Monoclonal Antibody
- 4.1.3 Anti-rabies Serum
- 4.2 Global Passive Immunizing Drugs Sales Volume by Type
- 4.2.1 Global Passive Immunizing Drugs Sales Volume by Type (2020 VS 2024 VS 2031)
- 4.2.2 Global Passive Immunizing Drugs Sales Volume by Type (2020-2031)
- 4.2.3 Global Passive Immunizing Drugs Sales Volume Share by Type (2020-2031)
- 4.3 Global Passive Immunizing Drugs Sales Value by Type
- 4.3.1 Global Passive Immunizing Drugs Sales Value by Type (2020 VS 2024 VS 2031)
- 4.3.2 Global Passive Immunizing Drugs Sales Value by Type (2020-2031)
- 4.3.3 Global Passive Immunizing Drugs Sales Value Share by Type (2020-2031)
- 5 Passive Immunizing Drugs Market by Application
- 5.1 Passive Immunizing Drugs Application Introduction
- 5.1.1 Category II Exposure
- 5.1.2 Category III Exposure
- 5.2 Global Passive Immunizing Drugs Sales Volume by Application
- 5.2.1 Global Passive Immunizing Drugs Sales Volume by Application (2020 VS 2024 VS 2031)
- 5.2.2 Global Passive Immunizing Drugs Sales Volume by Application (2020-2031)
- 5.2.3 Global Passive Immunizing Drugs Sales Volume Share by Application (2020-2031)
- 5.3 Global Passive Immunizing Drugs Sales Value by Application
- 5.3.1 Global Passive Immunizing Drugs Sales Value by Application (2020 VS 2024 VS 2031)
- 5.3.2 Global Passive Immunizing Drugs Sales Value by Application (2020-2031)
- 5.3.3 Global Passive Immunizing Drugs Sales Value Share by Application (2020-2031)
- 6 Passive Immunizing Drugs Regional Sales and Value Analysis
- 6.1 Global Passive Immunizing Drugs Sales by Region: 2020 VS 2024 VS 2031
- 6.2 Global Passive Immunizing Drugs Sales by Region (2020-2031)
- 6.2.1 Global Passive Immunizing Drugs Sales by Region: 2020-2025
- 6.2.2 Global Passive Immunizing Drugs Sales by Region (2026-2031)
- 6.3 Global Passive Immunizing Drugs Sales Value by Region: 2020 VS 2024 VS 2031
- 6.4 Global Passive Immunizing Drugs Sales Value by Region (2020-2031)
- 6.4.1 Global Passive Immunizing Drugs Sales Value by Region: 2020-2025
- 6.4.2 Global Passive Immunizing Drugs Sales Value by Region (2026-2031)
- 6.5 Global Passive Immunizing Drugs Market Price Analysis by Region (2020-2025)
- 6.6 North America
- 6.6.1 North America Passive Immunizing Drugs Sales Value (2020-2031)
- 6.6.2 North America Passive Immunizing Drugs Sales Value Share by Country, 2024 VS 2031
- 6.7 Europe
- 6.7.1 Europe Passive Immunizing Drugs Sales Value (2020-2031)
- 6.7.2 Europe Passive Immunizing Drugs Sales Value Share by Country, 2024 VS 2031
- 6.8 Asia-Pacific
- 6.8.1 Asia-Pacific Passive Immunizing Drugs Sales Value (2020-2031)
- 6.8.2 Asia-Pacific Passive Immunizing Drugs Sales Value Share by Country, 2024 VS 2031
- 6.9 South America
- 6.9.1 South America Passive Immunizing Drugs Sales Value (2020-2031)
- 6.9.2 South America Passive Immunizing Drugs Sales Value Share by Country, 2024 VS 2031
- 6.10 Middle East & Africa
- 6.10.1 Middle East & Africa Passive Immunizing Drugs Sales Value (2020-2031)
- 6.10.2 Middle East & Africa Passive Immunizing Drugs Sales Value Share by Country, 2024 VS 2031
- 7 Passive Immunizing Drugs Country-level Sales and Value Analysis
- 7.1 Global Passive Immunizing Drugs Sales by Country: 2020 VS 2024 VS 2031
- 7.2 Global Passive Immunizing Drugs Sales Value by Country: 2020 VS 2024 VS 2031
- 7.3 Global Passive Immunizing Drugs Sales by Country (2020-2031)
- 7.3.1 Global Passive Immunizing Drugs Sales by Country (2020-2025)
- 7.3.2 Global Passive Immunizing Drugs Sales by Country (2026-2031)
- 7.4 Global Passive Immunizing Drugs Sales Value by Country (2020-2031)
- 7.4.1 Global Passive Immunizing Drugs Sales Value by Country (2020-2025)
- 7.4.2 Global Passive Immunizing Drugs Sales Value by Country (2026-2031)
- 7.5 USA
- 7.5.1 USA Passive Immunizing Drugs Sales Value Growth Rate (2020-2031)
- 7.5.2 USA Passive Immunizing Drugs Sales Value Share by Type, 2024 VS 2031
- 7.5.3 USA Passive Immunizing Drugs Sales Value Share by Application, 2024 VS 2031
- 7.6 Canada
- 7.6.1 Canada Passive Immunizing Drugs Sales Value Growth Rate (2020-2031)
- 7.6.2 Canada Passive Immunizing Drugs Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Canada Passive Immunizing Drugs Sales Value Share by Application, 2024 VS 2031
- 7.7 Mexico
- 7.6.1 Mexico Passive Immunizing Drugs Sales Value Growth Rate (2020-2031)
- 7.6.2 Mexico Passive Immunizing Drugs Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Mexico Passive Immunizing Drugs Sales Value Share by Application, 2024 VS 2031
- 7.8 Germany
- 7.8.1 Germany Passive Immunizing Drugs Sales Value Growth Rate (2020-2031)
- 7.8.2 Germany Passive Immunizing Drugs Sales Value Share by Type, 2024 VS 2031
- 7.8.3 Germany Passive Immunizing Drugs Sales Value Share by Application, 2024 VS 2031
- 7.9 France
- 7.9.1 France Passive Immunizing Drugs Sales Value Growth Rate (2020-2031)
- 7.9.2 France Passive Immunizing Drugs Sales Value Share by Type, 2024 VS 2031
- 7.9.3 France Passive Immunizing Drugs Sales Value Share by Application, 2024 VS 2031
- 7.10 U.K.
- 7.10.1 U.K. Passive Immunizing Drugs Sales Value Growth Rate (2020-2031)
- 7.10.2 U.K. Passive Immunizing Drugs Sales Value Share by Type, 2024 VS 2031
- 7.10.3 U.K. Passive Immunizing Drugs Sales Value Share by Application, 2024 VS 2031
- 7.11 Italy
- 7.11.1 Italy Passive Immunizing Drugs Sales Value Growth Rate (2020-2031)
- 7.11.2 Italy Passive Immunizing Drugs Sales Value Share by Type, 2024 VS 2031
- 7.11.3 Italy Passive Immunizing Drugs Sales Value Share by Application, 2024 VS 2031
- 7.12 Spain
- 7.12.1 Spain Passive Immunizing Drugs Sales Value Growth Rate (2020-2031)
- 7.12.2 Spain Passive Immunizing Drugs Sales Value Share by Type, 2024 VS 2031
- 7.12.3 Spain Passive Immunizing Drugs Sales Value Share by Application, 2024 VS 2031
- 7.13 Russia
- 7.13.1 Russia Passive Immunizing Drugs Sales Value Growth Rate (2020-2031)
- 7.13.2 Russia Passive Immunizing Drugs Sales Value Share by Type, 2024 VS 2031
- 7.13.3 Russia Passive Immunizing Drugs Sales Value Share by Application, 2024 VS 2031
- 7.14 Netherlands
- 7.14.1 Netherlands Passive Immunizing Drugs Sales Value Growth Rate (2020-2031)
- 7.14.2 Netherlands Passive Immunizing Drugs Sales Value Share by Type, 2024 VS 2031
- 7.14.3 Netherlands Passive Immunizing Drugs Sales Value Share by Application, 2024 VS 2031
- 7.15 Nordic Countries
- 7.15.1 Nordic Countries Passive Immunizing Drugs Sales Value Growth Rate (2020-2031)
- 7.15.2 Nordic Countries Passive Immunizing Drugs Sales Value Share by Type, 2024 VS 2031
- 7.15.3 Nordic Countries Passive Immunizing Drugs Sales Value Share by Application, 2024 VS 2031
- 7.16 China
- 7.16.1 China Passive Immunizing Drugs Sales Value Growth Rate (2020-2031)
- 7.16.2 China Passive Immunizing Drugs Sales Value Share by Type, 2024 VS 2031
- 7.16.3 China Passive Immunizing Drugs Sales Value Share by Application, 2024 VS 2031
- 7.17 Japan
- 7.17.1 Japan Passive Immunizing Drugs Sales Value Growth Rate (2020-2031)
- 7.17.2 Japan Passive Immunizing Drugs Sales Value Share by Type, 2024 VS 2031
- 7.17.3 Japan Passive Immunizing Drugs Sales Value Share by Application, 2024 VS 2031
- 7.18 South Korea
- 7.18.1 South Korea Passive Immunizing Drugs Sales Value Growth Rate (2020-2031)
- 7.18.2 South Korea Passive Immunizing Drugs Sales Value Share by Type, 2024 VS 2031
- 7.18.3 South Korea Passive Immunizing Drugs Sales Value Share by Application, 2024 VS 2031
- 7.19 India
- 7.19.1 India Passive Immunizing Drugs Sales Value Growth Rate (2020-2031)
- 7.19.2 India Passive Immunizing Drugs Sales Value Share by Type, 2024 VS 2031
- 7.19.3 India Passive Immunizing Drugs Sales Value Share by Application, 2024 VS 2031
- 7.20 Australia
- 7.20.1 Australia Passive Immunizing Drugs Sales Value Growth Rate (2020-2031)
- 7.20.2 Australia Passive Immunizing Drugs Sales Value Share by Type, 2024 VS 2031
- 7.20.3 Australia Passive Immunizing Drugs Sales Value Share by Application, 2024 VS 2031
- 7.21 Southeast Asia
- 7.21.1 Southeast Asia Passive Immunizing Drugs Sales Value Growth Rate (2020-2031)
- 7.21.2 Southeast Asia Passive Immunizing Drugs Sales Value Share by Type, 2024 VS 2031
- 7.21.3 Southeast Asia Passive Immunizing Drugs Sales Value Share by Application, 2024 VS 2031
- 7.22 Brazil
- 7.22.1 Brazil Passive Immunizing Drugs Sales Value Growth Rate (2020-2031)
- 7.22.2 Brazil Passive Immunizing Drugs Sales Value Share by Type, 2024 VS 2031
- 7.22.3 Brazil Passive Immunizing Drugs Sales Value Share by Application, 2024 VS 2031
- 7.23 Argentina
- 7.23.1 Argentina Passive Immunizing Drugs Sales Value Growth Rate (2020-2031)
- 7.23.2 Argentina Passive Immunizing Drugs Sales Value Share by Type, 2024 VS 2031
- 7.23.3 Argentina Passive Immunizing Drugs Sales Value Share by Application, 2024 VS 2031
- 7.24 Chile
- 7.24.1 Chile Passive Immunizing Drugs Sales Value Growth Rate (2020-2031)
- 7.24.2 Chile Passive Immunizing Drugs Sales Value Share by Type, 2024 VS 2031
- 7.24.3 Chile Passive Immunizing Drugs Sales Value Share by Application, 2024 VS 2031
- 7.25 Colombia
- 7.25.1 Colombia Passive Immunizing Drugs Sales Value Growth Rate (2020-2031)
- 7.25.2 Colombia Passive Immunizing Drugs Sales Value Share by Type, 2024 VS 2031
- 7.25.3 Colombia Passive Immunizing Drugs Sales Value Share by Application, 2024 VS 2031
- 7.26 Peru
- 7.26.1 Peru Passive Immunizing Drugs Sales Value Growth Rate (2020-2031)
- 7.26.2 Peru Passive Immunizing Drugs Sales Value Share by Type, 2024 VS 2031
- 7.26.3 Peru Passive Immunizing Drugs Sales Value Share by Application, 2024 VS 2031
- 7.27 Saudi Arabia
- 7.27.1 Saudi Arabia Passive Immunizing Drugs Sales Value Growth Rate (2020-2031)
- 7.27.2 Saudi Arabia Passive Immunizing Drugs Sales Value Share by Type, 2024 VS 2031
- 7.27.3 Saudi Arabia Passive Immunizing Drugs Sales Value Share by Application, 2024 VS 2031
- 7.28 Israel
- 7.28.1 Israel Passive Immunizing Drugs Sales Value Growth Rate (2020-2031)
- 7.28.2 Israel Passive Immunizing Drugs Sales Value Share by Type, 2024 VS 2031
- 7.28.3 Israel Passive Immunizing Drugs Sales Value Share by Application, 2024 VS 2031
- 7.29 UAE
- 7.29.1 UAE Passive Immunizing Drugs Sales Value Growth Rate (2020-2031)
- 7.29.2 UAE Passive Immunizing Drugs Sales Value Share by Type, 2024 VS 2031
- 7.29.3 UAE Passive Immunizing Drugs Sales Value Share by Application, 2024 VS 2031
- 7.30 Turkey
- 7.30.1 Turkey Passive Immunizing Drugs Sales Value Growth Rate (2020-2031)
- 7.30.2 Turkey Passive Immunizing Drugs Sales Value Share by Type, 2024 VS 2031
- 7.30.3 Turkey Passive Immunizing Drugs Sales Value Share by Application, 2024 VS 2031
- 7.31 Iran
- 7.31.1 Iran Passive Immunizing Drugs Sales Value Growth Rate (2020-2031)
- 7.31.2 Iran Passive Immunizing Drugs Sales Value Share by Type, 2024 VS 2031
- 7.31.3 Iran Passive Immunizing Drugs Sales Value Share by Application, 2024 VS 2031
- 7.32 Egypt
- 7.32.1 Egypt Passive Immunizing Drugs Sales Value Growth Rate (2020-2031)
- 7.32.2 Egypt Passive Immunizing Drugs Sales Value Share by Type, 2024 VS 2031
- 7.32.3 Egypt Passive Immunizing Drugs Sales Value Share by Application, 2024 VS 2031
- 8 Company Profiles
- 8.1 Xingmeng Biopharmaceuticals (Suzhou)
- 8.1.1 Xingmeng Biopharmaceuticals (Suzhou) Comapny Information
- 8.1.2 Xingmeng Biopharmaceuticals (Suzhou) Business Overview
- 8.1.3 Xingmeng Biopharmaceuticals (Suzhou) Passive Immunizing Drugs Sales, Value and Gross Margin (2020-2025)
- 8.1.4 Xingmeng Biopharmaceuticals (Suzhou) Passive Immunizing Drugs Product Portfolio
- 8.1.5 Xingmeng Biopharmaceuticals (Suzhou) Recent Developments
- 8.2 Wuhan Institute of Biological Products
- 8.2.1 Wuhan Institute of Biological Products Comapny Information
- 8.2.2 Wuhan Institute of Biological Products Business Overview
- 8.2.3 Wuhan Institute of Biological Products Passive Immunizing Drugs Sales, Value and Gross Margin (2020-2025)
- 8.2.4 Wuhan Institute of Biological Products Passive Immunizing Drugs Product Portfolio
- 8.2.5 Wuhan Institute of Biological Products Recent Developments
- 8.3 Sichuan Yuanda Shuyang Pharmaceutical
- 8.3.1 Sichuan Yuanda Shuyang Pharmaceutical Comapny Information
- 8.3.2 Sichuan Yuanda Shuyang Pharmaceutical Business Overview
- 8.3.3 Sichuan Yuanda Shuyang Pharmaceutical Passive Immunizing Drugs Sales, Value and Gross Margin (2020-2025)
- 8.3.4 Sichuan Yuanda Shuyang Pharmaceutical Passive Immunizing Drugs Product Portfolio
- 8.3.5 Sichuan Yuanda Shuyang Pharmaceutical Recent Developments
- 8.4 Shanxi Kangbao Biological Product
- 8.4.1 Shanxi Kangbao Biological Product Comapny Information
- 8.4.2 Shanxi Kangbao Biological Product Business Overview
- 8.4.3 Shanxi Kangbao Biological Product Passive Immunizing Drugs Sales, Value and Gross Margin (2020-2025)
- 8.4.4 Shanxi Kangbao Biological Product Passive Immunizing Drugs Product Portfolio
- 8.4.5 Shanxi Kangbao Biological Product Recent Developments
- 8.5 Sharon Bio-Medicine
- 8.5.1 Sharon Bio-Medicine Comapny Information
- 8.5.2 Sharon Bio-Medicine Business Overview
- 8.5.3 Sharon Bio-Medicine Passive Immunizing Drugs Sales, Value and Gross Margin (2020-2025)
- 8.5.4 Sharon Bio-Medicine Passive Immunizing Drugs Product Portfolio
- 8.5.5 Sharon Bio-Medicine Recent Developments
- 8.6 Hualan Biological Engineering
- 8.6.1 Hualan Biological Engineering Comapny Information
- 8.6.2 Hualan Biological Engineering Business Overview
- 8.6.3 Hualan Biological Engineering Passive Immunizing Drugs Sales, Value and Gross Margin (2020-2025)
- 8.6.4 Hualan Biological Engineering Passive Immunizing Drugs Product Portfolio
- 8.6.5 Hualan Biological Engineering Recent Developments
- 8.7 North China Pharmaceutical
- 8.7.1 North China Pharmaceutical Comapny Information
- 8.7.2 North China Pharmaceutical Business Overview
- 8.7.3 North China Pharmaceutical Passive Immunizing Drugs Sales, Value and Gross Margin (2020-2025)
- 8.7.4 North China Pharmaceutical Passive Immunizing Drugs Product Portfolio
- 8.7.5 North China Pharmaceutical Recent Developments
- 8.8 Sinopharm Group
- 8.8.1 Sinopharm Group Comapny Information
- 8.8.2 Sinopharm Group Business Overview
- 8.8.3 Sinopharm Group Passive Immunizing Drugs Sales, Value and Gross Margin (2020-2025)
- 8.8.4 Sinopharm Group Passive Immunizing Drugs Product Portfolio
- 8.8.5 Sinopharm Group Recent Developments
- 8.9 Zydus Lifesciences
- 8.9.1 Zydus Lifesciences Comapny Information
- 8.9.2 Zydus Lifesciences Business Overview
- 8.9.3 Zydus Lifesciences Passive Immunizing Drugs Sales, Value and Gross Margin (2020-2025)
- 8.9.4 Zydus Lifesciences Passive Immunizing Drugs Product Portfolio
- 8.9.5 Zydus Lifesciences Recent Developments
- 8.10 Serum Institute of India
- 8.10.1 Serum Institute of India Comapny Information
- 8.10.2 Serum Institute of India Business Overview
- 8.10.3 Serum Institute of India Passive Immunizing Drugs Sales, Value and Gross Margin (2020-2025)
- 8.10.4 Serum Institute of India Passive Immunizing Drugs Product Portfolio
- 8.10.5 Serum Institute of India Recent Developments
- 8.11 Sanofi Pasteur
- 8.11.1 Sanofi Pasteur Comapny Information
- 8.11.2 Sanofi Pasteur Business Overview
- 8.11.3 Sanofi Pasteur Passive Immunizing Drugs Sales, Value and Gross Margin (2020-2025)
- 8.11.4 Sanofi Pasteur Passive Immunizing Drugs Product Portfolio
- 8.11.5 Sanofi Pasteur Recent Developments
- 8.12 Kedrion Biopharma
- 8.12.1 Kedrion Biopharma Comapny Information
- 8.12.2 Kedrion Biopharma Business Overview
- 8.12.3 Kedrion Biopharma Passive Immunizing Drugs Sales, Value and Gross Margin (2020-2025)
- 8.12.4 Kedrion Biopharma Passive Immunizing Drugs Product Portfolio
- 8.12.5 Kedrion Biopharma Recent Developments
- 8.13 Kamada
- 8.13.1 Kamada Comapny Information
- 8.13.2 Kamada Business Overview
- 8.13.3 Kamada Passive Immunizing Drugs Sales, Value and Gross Margin (2020-2025)
- 8.13.4 Kamada Passive Immunizing Drugs Product Portfolio
- 8.13.5 Kamada Recent Developments
- 8.14 Haffkine Bio-Pharmaceutical
- 8.14.1 Haffkine Bio-Pharmaceutical Comapny Information
- 8.14.2 Haffkine Bio-Pharmaceutical Business Overview
- 8.14.3 Haffkine Bio-Pharmaceutical Passive Immunizing Drugs Sales, Value and Gross Margin (2020-2025)
- 8.14.4 Haffkine Bio-Pharmaceutical Passive Immunizing Drugs Product Portfolio
- 8.14.5 Haffkine Bio-Pharmaceutical Recent Developments
- 8.15 Grifols
- 8.15.1 Grifols Comapny Information
- 8.15.2 Grifols Business Overview
- 8.15.3 Grifols Passive Immunizing Drugs Sales, Value and Gross Margin (2020-2025)
- 8.15.4 Grifols Passive Immunizing Drugs Product Portfolio
- 8.15.5 Grifols Recent Developments
- 8.16 Bharat Biotech
- 8.16.1 Bharat Biotech Comapny Information
- 8.16.2 Bharat Biotech Business Overview
- 8.16.3 Bharat Biotech Passive Immunizing Drugs Sales, Value and Gross Margin (2020-2025)
- 8.16.4 Bharat Biotech Passive Immunizing Drugs Product Portfolio
- 8.16.5 Bharat Biotech Recent Developments
- 9 Value Chain and Sales Channels Analysis
- 9.1 Passive Immunizing Drugs Value Chain Analysis
- 9.1.1 Passive Immunizing Drugs Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Passive Immunizing Drugs Sales Mode & Process
- 9.2 Passive Immunizing Drugs Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Passive Immunizing Drugs Distributors
- 9.2.3 Passive Immunizing Drugs Customers
- 10 Concluding Insights
- 11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.